Chronic Oral Study of Myosin Activation to Increase
Contractility in Heart Failure (COSMIC-HF): a phase 2,
pharmacokinetic, randomised, placebo-controlled trial

J 2016

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

TEERLINK, John R.; Michael G. FELKER; John J.V. MCMURRAY; Scott D. SOLOMON; Kirkwood F. Jr. ADAMS et al.

Základní údaje

Originální název

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

Autoři

Vydání

Lancet, New York, Elsevier Science Inc. 2016, 0140-6736

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 47.831

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00092316

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

COSMIC-HF

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 2. 2017 16:19, Soňa Böhmová

Anotace

V originále

Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. Methods In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512.

Citovat

TEERLINK, John R.; Michael G. FELKER; John J.V. MCMURRAY; Scott D. SOLOMON; Kirkwood F. Jr. ADAMS; John G.F. CLELAND; Justin A. EZEKOWITZ; Assen GOUDEV; Peter MACDONALD; Marco METRA; Veselin MITROVIC; Piotr PONIKOWSKI; Pranas SERPYTIS; Jindřich ŠPINAR; János TOMCSÁNYI; Hans J. VANDEKERCKHOVE; Adriaan A. VOORS; Maria Laura MONSALVO; James JOHNSTON; Fady I. MALIK a Narimon HONARPOUR. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. New York: Elsevier Science Inc., 2016, roč. 388, č. 10062, s. 2895-2903. ISSN 0140-6736. Dostupné z: https://doi.org/10.1016/S0140-6736(16)32049-9.

@article{1364895,
   author = {Teerlink, John R. and Felker, Michael G. and McMurray, John J.V. and Solomon, Scott D. and Adams, Kirkwood F. Jr. and Cleland, John G.F. and Ezekowitz, Justin A. and Goudev, Assen and Macdonald, Peter and Metra, Marco and Mitrovic, Veselin and Ponikowski, Piotr and Serpytis, Pranas and Špinar, Jindřich and Tomcsányi, János and Vandekerckhove, Hans J. and Voors, Adriaan A. and Monsalvo, Maria Laura and Johnston, James and Malik, Fady I. and Honarpour, Narimon},
   article_location = {New York},
   article_number = {10062},
   doi = {https://doi.org/10.1016/S0140-6736(16)32049-9},
   keywords = {COSMIC-HF},
   language = {eng},
   issn = {0140-6736},
   journal = {Lancet},
   title = {Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial},
   url = {http://www.sciencedirect.com/science/article/pii/S0140673616320499},
   volume = {388},
   year = {2016}
}

TY  - JOUR
ID  - 1364895
AU  - Teerlink, John R. - Felker, Michael G. - McMurray, John J.V. - Solomon, Scott D. - Adams, Kirkwood F. Jr. - Cleland, John G.F. - Ezekowitz, Justin A. - Goudev, Assen - Macdonald, Peter - Metra, Marco - Mitrovic, Veselin - Ponikowski, Piotr - Serpytis, Pranas - Špinar, Jindřich - Tomcsányi, János - Vandekerckhove, Hans J. - Voors, Adriaan A. - Monsalvo, Maria Laura - Johnston, James - Malik, Fady I. - Honarpour, Narimon
PY  - 2016
TI  - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
JF  - Lancet
VL  - 388
IS  - 10062
SP  - 2895-2903
EP  - 2895-2903
PB  - Elsevier Science Inc.
SN  - 01406736
KW  - COSMIC-HF
UR  - http://www.sciencedirect.com/science/article/pii/S0140673616320499
N2  - Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil. Methods In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512.
ER  -

TEERLINK, John R.; Michael G. FELKER; John J.V. MCMURRAY; Scott D. SOLOMON; Kirkwood F. Jr. ADAMS; John G.F. CLELAND; Justin A. EZEKOWITZ; Assen GOUDEV; Peter MACDONALD; Marco METRA; Veselin MITROVIC; Piotr PONIKOWSKI; Pranas SERPYTIS; Jindřich ŠPINAR; János TOMCSÁNYI; Hans J. VANDEKERCKHOVE; Adriaan A. VOORS; Maria Laura MONSALVO; James JOHNSTON; Fady I. MALIK a Narimon HONARPOUR. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. \textit{Lancet}. New York: Elsevier Science Inc., 2016, roč.~388, č.~10062, s.~2895-2903. ISSN~0140-6736. Dostupné z: https://doi.org/10.1016/S0140-6736(16)32049-9.

Přehled o publikaci